Objective:

To evaluate TB rates in pediatric HSCT recipients and the role of isoniazid (INH) prophylaxis in high-risk LTBI patients, focusing on specific outcomes such as incidence rates and reactivation cases.

Approach:

Key Findings:

• INH prophylaxis significantly reduced the incidence of post-HSCT TB reactivation in high-risk patients, with a reduction of X% (insert specific percentage).
• No patients in the study developed active TB during the follow-up period.
• Drug-related toxicities were minimal and manageable.

Interpretation:

The study supports the efficacy of INH prophylaxis in preventing TB reactivation in pediatric HSCT recipients at high risk for LTBI, with acceptable toxicity levels.

Limitations:

• Retrospective design may introduce bias, potentially affecting the reliability of the findings.
• Limited generalizability due to single-center study, which may not reflect broader populations.

Conclusion:

Isoniazid prophylaxis is effective in reducing TB reactivation in high-risk pediatric HSCT patients, highlighting the need for targeted TB prevention strategies in this vulnerable population, which could inform clinical guidelines.

Source

Based on findings from:

Efficacy of Isoniazid Prophylaxis in Pediatric Patients at High Risk for LTBI Undergoing Hematopoietic Stem Cell Transplantation

Uet Yu, Jiaming Yu, Xindan Lian, Yu Liu, Xiaodong Wang, Qian Zhang, Chunjing Wang, Chunlan Yang, Yue Li, Xiaohui Zhou, Xiaoling Zhang, Sixi Liu. Bmc Infectious Diseases, 2026.

https://link.springer.com/article/10.1186/s12879-026-12643-w

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.